Form 6-K DR REDDYS LABORATORIES For: Jul 22

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

July 2026

 

Commission File Number 1-15182

 

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

 

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F    x

Form 40-F    ¨

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes    ¨

No    x

 

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

 

  

DISCLOSURE OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION

 

We hereby furnish the United States Securities and Exchange Commission with copies of the following information about our public disclosures regarding our results of operations and financial condition for the quarter ended June 30, 2026.

 

On July 22, 2026, we announced our results of operations for the quarter ended June 30, 2026. We issued a press release announcing our results under International Financial Reporting Standards (“IFRS”), IFRS Unaudited Consolidated Financial Results, Ind AS Unaudited Consolidated Financial Results with review report and Ind AS Unaudited Standalone Financial Results with review report for the quarter ended June 30, 2026, a copy of which is attached to this Form 6-K as Exhibit 99.2 , 99.3 , 99.4 and 99.5 respectively. 

 

We have also made available to the public on our web site, www.drreddys.com, the following: IFRS Unaudited Consolidated Financial Results, Ind AS Unaudited Consolidated Financial Results and Ind AS Unaudited Standalone Financial Results for the quarter ended June 30, 2026.

 

Exhibits

 

Exhibit Number		Description of Exhibits
99.1		Outcome of the Board Meeting held on July 22, 2026
99.2		Press Release, “Dr. Reddy’s Q1 FY2027 Financial Results”, July 22, 2026.
99.3		IFRS Unaudited Consolidated Financial Results for the quarter ended June 30, 2026.
99.4		Ind AS Unaudited Consolidated Financial Results for the quarter ended June 30, 2026.
99.5		Ind AS Unaudited Standalone Financial Results for the quarter ended June 30, 2026.

 

  

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

		DR. REDDY’S LABORATORIES LIMITED (Registrant)
Date:  July 22, 2026		By:	/s/ K Randhir Singh
			Name:	K Randhir Singh
			Title:	Company Secretary & Compliance Officer

 

 

 

ATTACHMENTS / EXHIBITS

EXHIBIT 99.1

EXHIBIT 99.2

EXHIBIT 99.3

EXHIBIT 99.4

EXHIBIT 99.5

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Breakthrough T1D Run 2026-2027 Season Launches, Uniting Runners Worldwide to Fund Type 1 Diabetes Research
• InventHelp Inventors Develop New Snake Wrench (FDD-129)
• Veterans United Home Loans Named No. 8 on PEOPLE Companies that Care® List